A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer

The purpose of this research study is to find out if adding radiation prior to chemoimmunotherapy and surgery is effective for people with non-small cell lung cancer (NSCLC) who have the potential for surgery. Standard of Care Chemoimmunotherapy: For this study, standard of care chemotherapy will be used. This means this is the type of chemotherapy that is normal for your cancer. In addition to the chemotherapy, you will also receive the immunotherapy drug, nivolumab. This will be administered intravenously once every 3 weeks for up to 3 cycles (i.e. 9 weeks of total systemic therapy), prior

Trial Details

NCT ID
NCT06800339
Phase
PHASE1
Sponsor
University of Maryland, Baltimore
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Nivolumab
  • Chemotherapy
  • SBRT
  • Surgical Resection
Locations (sample)
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • Bel Air, Maryland, United States|39.53594,-76.34829
  • Glen Burnie, Maryland, United States|39.16261,-76.62469

Key Eligibility Criteria

  • Age greater than or equal to18 years at time of study entry
  • Eastern cooperative oncology group (ECOG) performance status of 0 or 1
  • Participants with histologically confirmed stage II-IIIC(N3) NSCLC (per the 8th International Association for the Study of Lung Cancer) with diseas…
  • a. Patients with intrathoracic, contralateral N3 disease will be allowed to enroll (see exclusion criteria for further details)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →